The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC).
Mark G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Clovis; Novartis; Pfizer; Roche
Research Funding - Boehringer Ingelheim; Pfizer
Geoffrey R. Oxnard
Consultant or Advisory Role - Boehringer Ingelheim; Genentech
Bruce E. Johnson
Stock Ownership - KEW Group
Honoraria - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Transgenomic
Other Remuneration - Response Genetics
Lynne D Berry
No relevant relationships to disclose
Heidi Chen
No relevant relationships to disclose
David J. Kwiatkowski
Consultant or Advisory Role - Novartis
Honoraria - Millennium
Research Funding - Millennium
Anthony John Iafrate
Consultant or Advisory Role - Bio-Reference Laboratories; Pfizer
Ignacio Ivan Wistuba
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Johnson & Johnson; Pfizer; Roche; Sanofi
Wilbur A. Franklin
No relevant relationships to disclose
Dara Aisner
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Abbott Molecular; Boehringer Ingelheim; Pfizer
Lecia V. Sequist
No relevant relationships to disclose
Fadlo Raja Khuri
No relevant relationships to disclose
Edward B. Garon
No relevant relationships to disclose
William Pao
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis; MolecularMD; Symphony Evolution
Research Funding - AstraZeneca; Bristol-Myers Squibb; Clovis; Enzon; Symphogen; Xcovery
Other Remuneration - MolecularMD
Charles M. Rudin
Consultant or Advisory Role - Lilly; Oncothyreon
Joan H. Schiller
No relevant relationships to disclose
Eric B. Haura
No relevant relationships to disclose
John D. Minna
Consultant or Advisory Role - Amgen
Paul A. Bunn
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi